Literature DB >> 33706940

Effects of nicotine on DARPP-32 and CaMKII signaling relevant to addiction.

Angela M Lee1, Marina R Picciotto2.   

Abstract

Paul Greengard brought to neuroscience the idea of, and evidence for, the role of second messenger systems in neuronal signaling. The fundamental nature of his contributions is evident in the far reach of his work, relevant to various subfields and topics in neuroscience. In this review, we discuss some of Greengard's work from the perspective of nicotinic acetylcholine receptors and their relevance to nicotine addiction. Specifically, we review the roles of dopamine- and cAMP-regulated phospho-protein of 32kDa (DARPP-32) and Ca2+/calmodulin-dependent kinase II (CaMKII) in nicotine-dependent behaviors. For each protein, we discuss the historical context of their discovery and initial characterization, focusing on the extensive biochemical and immunohistochemical work conducted by Greengard and colleagues. We then briefly summarize contemporary understanding of each protein in key intracellular signaling cascades and evidence for the role of each protein with respect to systems and behaviors relevant to nicotine addiction.
© 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Addiction; CaMKII; Calcium; DARPP-32; Nicotine; cAMP

Mesh:

Substances:

Year:  2020        PMID: 33706940      PMCID: PMC8008986          DOI: 10.1016/bs.apha.2020.09.002

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  140 in total

Review 1.  Nicotinic acetylcholine receptors and the regulation of neuronal signalling.

Authors:  Federico Dajas-Bailador; Susan Wonnacott
Journal:  Trends Pharmacol Sci       Date:  2004-06       Impact factor: 14.819

2.  Nicotine regulates DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) phosphorylation at multiple sites in neostriatal neurons.

Authors:  Miho Hamada; Joseph P Hendrick; Gregory R Ryan; Mahomi Kuroiwa; Hideho Higashi; Masatoshi Tanaka; Angus C Nairn; Paul Greengard; Akinori Nishi
Journal:  J Pharmacol Exp Ther       Date:  2005-07-22       Impact factor: 4.030

3.  Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission.

Authors:  J W Kebabian; P Greengard
Journal:  Science       Date:  1971-12-24       Impact factor: 47.728

4.  Regulation of phosphorylation of proteins I, IIIa, and IIIb in rat neurohypophysis in vitro by electrical stimulation and by neuroactive agents.

Authors:  K Tsou; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

5.  Biochemical and immunochemical evidence that the "major postsynaptic density protein" is a subunit of a calmodulin-dependent protein kinase.

Authors:  M B Kennedy; M K Bennett; N E Erondu
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

6.  Nicotine activates and desensitizes midbrain dopamine neurons.

Authors:  V I Pidoplichko; M DeBiasi; J T Williams; J A Dani
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

7.  Long-term potentiation of excitatory inputs to brain reward areas by nicotine.

Authors:  H D Mansvelder; D S McGehee
Journal:  Neuron       Date:  2000-08       Impact factor: 17.173

8.  Smoking and mortality--beyond established causes.

Authors:  Brian D Carter; Christian C Abnet; Diane Feskanich; Neal D Freedman; Patricia Hartge; Cora E Lewis; Judith K Ockene; Ross L Prentice; Frank E Speizer; Michael J Thun; Eric J Jacobs
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

Review 9.  Emerging role of CaMKII in neuropsychiatric disease.

Authors:  A J Robison
Journal:  Trends Neurosci       Date:  2014-07-30       Impact factor: 13.837

10.  Exploring the nicotinic acetylcholine receptor-associated proteome with iTRAQ and transgenic mice.

Authors:  Tristan D McClure-Begley; Kathy L Stone; Michael J Marks; Sharon R Grady; Christopher M Colangelo; Jon M Lindstrom; Marina R Picciotto
Journal:  Genomics Proteomics Bioinformatics       Date:  2013-07-25       Impact factor: 7.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.